Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 559 across all filing types
Latest filing 2019-12-09 Regulatory Filings
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes announcements of press releases regarding preclinical data and study results, attached as exhibits. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is relatively short (3887 characters) and primarily serves to announce recent company developments and press releases. This fits the definition of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories.
2019-12-09 English
FORM 4
Director's Dealing
2019-11-18 English
FORM 3
Director's Dealing
2019-11-18 English
Director's Dealing 2019
Director's Dealing
2019-11-12 English
10-Q
Interim / Quarterly Report Q3 2019
2019-11-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated November 12, 2019, reporting the issuance of a press release announcing financial results for the quarter ended September 30, 2019. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not "filed" for purposes of certain Securities Exchange Act sections, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3768 characters, which is relatively short and consistent with an announcement rather than a full earnings release. The content corresponds to an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER).
2019-11-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.